JPWO2019178078A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019178078A5 JPWO2019178078A5 JP2020548920A JP2020548920A JPWO2019178078A5 JP WO2019178078 A5 JPWO2019178078 A5 JP WO2019178078A5 JP 2020548920 A JP2020548920 A JP 2020548920A JP 2020548920 A JP2020548920 A JP 2020548920A JP WO2019178078 A5 JPWO2019178078 A5 JP WO2019178078A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cell
- domain
- amino acid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023198981A JP7745616B2 (ja) | 2018-03-14 | 2023-11-24 | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643055P | 2018-03-14 | 2018-03-14 | |
| US62/643,055 | 2018-03-14 | ||
| PCT/US2019/021823 WO2019178078A1 (en) | 2018-03-14 | 2019-03-12 | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198981A Division JP7745616B2 (ja) | 2018-03-14 | 2023-11-24 | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518108A JP2021518108A (ja) | 2021-08-02 |
| JP2021518108A5 JP2021518108A5 (https=) | 2022-03-18 |
| JPWO2019178078A5 true JPWO2019178078A5 (https=) | 2022-03-18 |
| JP7438123B2 JP7438123B2 (ja) | 2024-02-26 |
Family
ID=67908477
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548920A Active JP7438123B2 (ja) | 2018-03-14 | 2019-03-12 | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
| JP2023198981A Active JP7745616B2 (ja) | 2018-03-14 | 2023-11-24 | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198981A Active JP7745616B2 (ja) | 2018-03-14 | 2023-11-24 | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12152079B2 (https=) |
| EP (1) | EP3765041A4 (https=) |
| JP (2) | JP7438123B2 (https=) |
| KR (1) | KR102805003B1 (https=) |
| CN (1) | CN112236151A (https=) |
| AU (1) | AU2019234573B2 (https=) |
| BR (1) | BR112020018670A2 (https=) |
| CA (1) | CA3093810A1 (https=) |
| EA (1) | EA202091982A1 (https=) |
| IL (2) | IL277267B2 (https=) |
| MX (1) | MX2020009463A (https=) |
| SG (1) | SG11202008795SA (https=) |
| WO (1) | WO2019178078A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202008926RA (en) | 2018-03-14 | 2020-10-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
| EP3842461A1 (en) * | 2019-12-23 | 2021-06-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
| KR20230022411A (ko) * | 2020-05-12 | 2023-02-15 | 라이엘 이뮤노파마, 인크. | 키메라 항원 수용체 스페이서 |
| CN115246883B (zh) * | 2021-02-02 | 2025-04-11 | 浙江理工大学 | 一种抗人源IL13Ra2鲨鱼单域抗体或其抗原结合片段和应用 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| JP2024514101A (ja) * | 2021-04-01 | 2024-03-28 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｉｌ－１３ｒａ２キメラ抗原受容体および使用方法 |
| JP2024527539A (ja) * | 2021-07-01 | 2024-07-25 | 寧波茂行生物医薬科技有限公司 | ＩＬ１３Ｒα２を標的としたユニバーサルＣＡＲ－Ｔ細胞及びその製造方法と使用 |
| CN116589585B (zh) * | 2021-12-29 | 2023-11-24 | 华道(上海)生物医药有限公司 | 一种抗IL13Ra2的纳米抗体及其应用 |
| CN114014941B (zh) * | 2022-01-10 | 2022-04-12 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
| WO2023138666A1 (en) * | 2022-01-19 | 2023-07-27 | Utc Therapeutics (Shanghai) Co., Ltd. | Circular rna and use thereof |
| CN114990069B (zh) * | 2022-05-17 | 2023-09-22 | 郑州大学第一附属医院 | 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用 |
| CN114805581B (zh) * | 2022-06-29 | 2022-10-14 | 上海优替济生生物医药有限公司 | 靶向il13ra2的抗体、嵌合抗原受体及其用途 |
| CN119654345A (zh) * | 2022-08-25 | 2025-03-18 | 南京传奇生物科技有限公司 | 靶向白介素13受体亚基α2的嵌合抗原受体及其使用方法 |
| CN115960257B (zh) * | 2022-09-29 | 2023-10-27 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的经优化的嵌合抗原受体及其用途 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025154925A1 (ko) * | 2024-01-18 | 2025-07-24 | 엑셀라몰(주) | IL13Ra2에 결합하는 폴리펩타이드 약물 접합체 및 이의 용도 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| DK2496698T3 (en) | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| CN104936621A (zh) | 2012-11-07 | 2015-09-23 | 辉瑞公司 | 抗IL-13受体α2抗体和抗体-药物缀合物 |
| JP6345688B2 (ja) | 2012-12-05 | 2018-06-20 | ソラ・バイオサイエンシズ・エルエルシー | タンパク質発現増強ポリペプチド |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| TWI805109B (zh) * | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| CN107002084B (zh) | 2014-09-19 | 2021-09-10 | 希望之城公司 | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 |
| JP7264592B2 (ja) * | 2015-01-26 | 2023-04-25 | ザ ユニバーシティー オブ シカゴ | ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用 |
| EP3324984A4 (en) * | 2015-07-21 | 2019-03-27 | City of Hope | T-LYMPHOCYTES FOR THE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS |
| JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
| ES2879700T3 (es) | 2016-02-05 | 2021-11-22 | Hope City | Administración de células T genomanipuladas para el tratamiento de cánceres en el sistema nervioso central |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| MA45779A (fr) | 2016-07-29 | 2019-06-05 | Juno Therapeutics Inc | Polypeptides immunomdulateurs et compositions et procédés associés |
| WO2018156711A1 (en) * | 2017-02-22 | 2018-08-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Il13ra2-binding chimeric antigen receptors |
| SG11202008926RA (en) | 2018-03-14 | 2020-10-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
-
2019
- 2019-03-12 WO PCT/US2019/021823 patent/WO2019178078A1/en not_active Ceased
- 2019-03-12 CA CA3093810A patent/CA3093810A1/en active Pending
- 2019-03-12 IL IL277267A patent/IL277267B2/en unknown
- 2019-03-12 US US16/979,471 patent/US12152079B2/en active Active
- 2019-03-12 IL IL314877A patent/IL314877B1/en unknown
- 2019-03-12 MX MX2020009463A patent/MX2020009463A/es unknown
- 2019-03-12 JP JP2020548920A patent/JP7438123B2/ja active Active
- 2019-03-12 KR KR1020207028966A patent/KR102805003B1/ko active Active
- 2019-03-12 SG SG11202008795SA patent/SG11202008795SA/en unknown
- 2019-03-12 EA EA202091982A patent/EA202091982A1/ru unknown
- 2019-03-12 CN CN201980031550.0A patent/CN112236151A/zh active Pending
- 2019-03-12 EP EP19768040.8A patent/EP3765041A4/en active Pending
- 2019-03-12 BR BR112020018670-8A patent/BR112020018670A2/pt unknown
- 2019-03-12 AU AU2019234573A patent/AU2019234573B2/en active Active
-
2023
- 2023-11-24 JP JP2023198981A patent/JP7745616B2/ja active Active
-
2024
- 2024-10-16 US US18/917,176 patent/US20250043013A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518108A5 (https=) | ||
| IL314877A (en) | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy | |
| US11618776B2 (en) | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains | |
| JP7082574B2 (ja) | 免疫療法用改変細胞 | |
| AU2017302668B9 (en) | Combination therapies of chimeric antigen receptors and PD-1 inhibitors | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JPWO2019178078A5 (https=) | ||
| JP5851419B2 (ja) | ヘテロダイマー結合タンパク質およびその使用 | |
| JP2019525771A5 (https=) | ||
| JP2015527070A5 (https=) | ||
| US20230235064A1 (en) | Bispecific immune cell engagers with binding specificity for hla-g and another antigen | |
| JP2021523949A5 (https=) | ||
| EP4469478A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| EP4606384A1 (en) | Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment | |
| JP2021518111A5 (https=) | ||
| JPWO2019219064A5 (https=) | ||
| US20230265185A1 (en) | Anti-cd22 single domain antibodies and therapeutic constructs | |
| JPWO2019178085A5 (https=) | ||
| JPWO2022235662A5 (https=) | ||
| HK40127540A (en) | Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment | |
| RU2809160C2 (ru) | Виды комбинированной терапии с использованием химерных антигенных рецепторов и ингибиторов pd-1 | |
| JP2025524457A (ja) | 哺乳動物におけるキメラ抗原受容体介在性の免疫応答を刺激するための方法において使用するためのｃｄ１２３に対する標的化モジュール | |
| WO2025006562A1 (en) | Methods of car administration and treatment | |
| CN117999344A (zh) | Nkg2d嵌合抗原受体和pd1抑制剂联合治疗癌症的方法和药物 | |
| HK40084551A (en) | Il2rbeta/common gamma chain antibodies |